Pfizer (NYSE:PFE) Trading 1.4% Higher - Here's Why

Key Points

• PFE rose 1.4% to about $27.47 mid‑day with roughly 32.9 million shares changing hands, a ~27% decline from its average daily volume.
• Investors are weighing a strong oncology franchise and a new Phase 1 filing as upside catalysts against a near‑term headwind from a paused updated COVID‑19 shot trial and renewed negative analyst commentary.
• Pfizer beat Q4 estimates (EPS $0.66 vs $0.57, revenue $17.56B vs $16.93B), but the street consensus remains a "Hold" with an average target of about $28.19.

Pfizer Inc. (NYSE:PFE - Get Free Report) rose 1.4% during mid-day trading on Wednesday . The company traded as high as $27.49 and last traded at $27.4710. Approximately 32,860,882 shares traded hands during mid-day trading, a decline of 27% from the average daily volume of 45,279,406 shares. The stock had previously closed at $27.10.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong oncology franchise and pipeline could support upside around upcoming Q1 results — Pfizer has a deep, multi‑modality oncology portfolio (approved drugs + ADCs, small molecules, immuno‑oncology candidates) that investors view as a durable revenue and growth driver. How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results
• Positive Sentiment: Ongoing R&D activity: Pfizer filed a new Phase 1 study (PF‑07328948), underscoring continued pipeline investment and potential future catalysts beyond established franchises. Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment
• Neutral Sentiment: Corporate housekeeping in India (Pfizer Limited) — a special window for dematerialisation of physical shares was announced; limited direct impact on NYSE-listed PFE. Pfizer Limited Opens Special Window for Dematerialisation of Physical Shares
• Neutral Sentiment: CEO Albert Bourla’s comments on global research competitiveness highlight strategic priorities but are not an immediate stock mover. Only one U.S. university ranks in the world’s top 10 in STEM. Pfizer’s CEO is calling for change
• Neutral Sentiment: Sector and index movement are influencing PFE trading — some coverage points to S&P 500 correlation rather than company‑specific drivers. Pfizer Inc. NYSE: PFE Market Action Tied To S&P 500 Index Movement
• Negative Sentiment: Analyst pressure: RBC Capital reaffirmed a sell rating on PFE, and at least one analyst reiterated a bearish stance this week — analyst downgrades and negative notes can increase selling pressure. RBC Capital Reaffirms Their Sell Rating on Pfizer (PFE)
• Negative Sentiment: Clinical setback: Pfizer and its COVID‑19 vaccine partner paused an updated‑shot trial, a near‑term pipeline disappointment that likely contributed to recent intraday weakness. The same coverage also flags Washington policy risk (reports of potential harsh tariffs on drugmakers without pricing deals) that could pressure margins and sentiment. Why Is Pfizer Stock Dropping Tuesday?
• Negative Sentiment: Recent price weakness noted across coverage — headlines pointing to PFE declines despite broader market gains highlight investor concern over the items above, amplifying volatility. Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. Royal Bank Of Canada initiated coverage on shares of Pfizer in a report on Tuesday, February 24th. They issued an "underperform" rating and a $25.00 target price on the stock. Bank of America cut their target price on shares of Pfizer from $29.00 to $28.00 and set a "neutral" rating on the stock in a report on Monday, December 15th. Argus raised shares of Pfizer from a "hold" rating to a "buy" rating and set a $35.00 target price on the stock in a report on Monday, March 2nd. Cantor Fitzgerald reissued a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a report on Wednesday, February 4th. Finally, HSBC raised their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a "buy" rating in a report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $28.19.

Pfizer Stock Performance

The stock has a fifty day moving average price of $27.14 and a two-hundred day moving average price of $25.89. The company has a market cap of $156.21 billion, a P/E ratio of 20.20 and a beta of 0.43. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analysts' expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 earnings per share. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pfizer

A number of hedge funds have recently made changes to their positions in PFE. Fiduciary Alliance LLC raised its holdings in Pfizer by 46.4% during the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company's stock worth $3,701,000 after purchasing an additional 46,043 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Pfizer in the third quarter valued at $3,019,000. Kepler Cheuvreux Suisse SA bought a new stake in shares of Pfizer during the 3rd quarter worth $16,613,000. Money Concepts Capital Corp boosted its stake in shares of Pfizer by 29.9% during the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company's stock worth $6,325,000 after acquiring an additional 57,188 shares in the last quarter. Finally, Vista Investment Partners LLC boosted its stake in shares of Pfizer by 236.1% during the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company's stock worth $1,774,000 after acquiring an additional 48,900 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.